Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QLH12016 in metastatic castration resistant prostate cancer
NCT05973149Phase 1Not yet recruiting
- Sponsor
- Qilu Pharmaceutical
- Start
- Aug 2023
- Primary completion
- Aug 2025
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
- Countries
- 1
01
Overview
Phase 1, open-label trial of QLH12016 in metastatic castration-resistant prostate cancer (mCRPC) (4 arms), sponsored by Qilu Pharmaceutical. Primary endpoints: Incidence of Dose Limiting Toxicities at 28 days, Maximum Tolerated Dose at 28 days and 5 more. Planned start Aug 2023; status: not yet recruiting.
02
Drugs
QLH12016
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT05973149.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05973149.